1. Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W (2013) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20:102–108
2. Birkmayer W, Hornykiewicz O (1961) The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73:787–788
3. Birkmayer W, Mentasti M (1967) Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes). Arch Psychiatr Nervenkr 210:29–35
4. Cadar D, Jellinger KA, Riederer P, Strobel S, Monoranu CM, Tappe D (2021) No Metagenomic evidence of causative viral pathogens in postencephalitic parkinsonism following encephalitis lethargica. Microorganisms 9:1716
5. Cardoso F, Goetz CG, Mestre TA, Sampaio C, Adler CH, Berg D, Bloem BR, Burn DJ, Fitts MS, Gasser T, Klein C, de Tijssen MAJ, Lang AE, Lim SY, Litvan I, Meissner WG, Möllenhauer B, Okubadejo N, Okun MS, Postuma RB, Svenningsson P, Tan LCS, Tsunemi T, Wahlström-Helgren S, Gershanik OS, Fung VSC, Trenkwalder C (2023) A Statement of the MDS on biological definition, staging, and classification of Parkinson’s disease. Mov Disord 9:259–266